Phase I Study of 2',3'-Dideoxyinosine: Experience with 19 Patients at New York University Medical Center

occurred at dosages higher than those associated with decreases in levels of p24 antigen. The major toxic effects of ddl are different from those associated with zidovudine. At the proper dosage, ddl may prove to be an effective agent for the chronic treatment of infection with human immunodeficiency virus and should be especially useful in the treatment of patients who cannot tolerate zidovudine. The chronic administration of the dideoxynucleoside analogue zidovudine has been shown to be clin